Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers

Neurobiology of Aging

Volumn 29, Issue 9, 2008, Pages 1334-1347

  De Felice, Fernanda G ^a,b   Wu, Diana ^a   Lambert, Mary P ^a   Fernandez, Sara J ^a   Velasco, Pauline T ^a   Lacor, Pascale N ^a   Bigio, Eileen H ^c   Jerecic, Jasna ^d   Acton, Paul J ^e   Shughrue, Paul J ^e   Chen Dodson, Elizabeth ^e   Kinney, Gene G ^e   Klein, William L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Acumen Pharmaceuticals Inc   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

A oligomers; Alzheimer's disease; Hippocampal neurons; PI3K; Src; Tau hyperphosphorylation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; AMYLOID BETA PROTEIN[1-42]; EPITOPE; MONOCLONAL ANTIBODY; NEUROTOXIN; OLIGOMER; PROTEIN TYROSINE KINASE; TAU PROTEIN;

ALZHEIMER DISEASE; AQUEOUS SOLUTION; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL CULTURE; CONTROLLED STUDY; FIBER; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; NERVE CELL; NERVE CELL CULTURE; NEUROBLASTOMA CELL; PATHOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CELLS, CULTURED; HIPPOCAMPUS; HUMANS; NEURONS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 47049120422     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.02.029     Document Type: Article

References (57)

1. Abramoff M.D., Magelhaes P.J., and Ram S.J. Image processing with image. J. Biophotonics Int. 11 (2004) 36-42
2. Ávila J., Lucas J.J., Perez M., and Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84 (2004) 361-384
3. Baki L., Shioi J., Wen P., Shao Z., Schwarzman A., Gama-Sosa M., Neve R., and Robakis N.K. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 23 (2004) 2586-2596
4. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 (2000) 916-919
5. Berg M.M., Krafft G.A., and Klein W.L. Rapid impact of beta-amyloid on paxillin in a neural cell line. J. Neurosci. Res. 50 (1997) 979-989
6. Bi X., Liu J., Yao Y., Baudry M., and Lynch G. Deregulation of the phosphatidylinositol-3 kinase signaling cascade is associated with neurodegeneration in npc1-/- mouse brain. Am. J. Pathol. 167 (2005) 1081-1092
7. Boutaud O., Montine T.J., Chang L., Klein W.L., and Oates J.A. PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. J. Neurochem. 96 (2006) 917-923
8. Busciglio J., Lorenzo A., Yeh J., and Yankner B.A. Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14 (1995) 879-888
9. Chen H.C., and Guan J.L. Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 10148-10152
10. Chromy B.A., Nowak R.J., Lambert M.P., Viola K.L., Chang L., Velasco P.T., Jones B.W., Fernandez S.J., Lacor P.N., Horowitz P., Finch C.E., Krafft G.A., and Klein W.L. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42 (2003) 12749-12760
11. De Felice, F.G., Velasco, P.T., Lambert, M.P., Viola, K.L., Fernandez, S.J., Ferreira, S.T., Klein, W.L. Abeta oligomers induce neuronal oxidative stress through an NMDA receptor-dependent mechanism that is blocked by the Alzheimer's drug memantine. J. Biol. Chem., in press.
12. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., and Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5 (2002) 452-457
13. Geula C., Wu C.K., Saroff D., Lorenzo A., Yuan M., and Yankner B.A. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 4 (1998) 827-831
14. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., and Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 10417-10422
15. Gotz J., Chen F., van Dorpe J., and Nitsch R.M. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta 42 fibrils. Science 293 (2001) 1491-1495
16. Grace E.A., and Busciglio J. Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. J. Neurosci. 23 (2003) 493-502
17. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'Connor R., and O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 93 (2005) 105-117
18. Hampel H., Buerger K., Zinkowski R., Teipel S.J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., Ohno H., Vanmechelen E., Vanderstichele H., McCulloch C., Moller H.J., Davies P., and Blennow K. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 61 (2004) 95-102
19. Hampel H., Goernitz A., and Buerger K. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Res. Bull. 61 (2003) 243-253
20. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
21. Harris F.M., Brecht W.J., Xu Q., Mahley R.W., and Huang Y. Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc. J. Biol. Chem. 279 (2004) 44795-44801
22. Hoshi M., Sato M., Matsumoto S., Noguchi A., Yasutake K., Yoshida N., and Sato K. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc. Natl. Acad. Sci. U.S.A. 27 (2003) 6370-6375
23. Impey S., Obrietan K., and Storm D.R. Making new connections: role of ERK/MAP kinase signaling in neuronal plasticity. Neuron 23 (1999) 11-14
24. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., and Westaway D. Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
25. Klein W.L., Krafft G.A., and Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 24 (2001) 219-224
26. Klein W.L., Stine WBJr, and Teplow D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging 25 (2004) 569-580
27. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Younkin S., and Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22 (2002) 6331-6335
28. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., Krafft G.A., and Klein W.L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 24 (2004) 10191-10200
29. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 6448-6453
30. Lambert M.P., Stevens G., Sabo S., Barber K., Wang G., Wade W., Krafft G., Snyder S., Holzman T.F., and Klein W.L. Beta/A4-evoked degeneration of differentiated SH-SY5Y human neuroblastoma cells. J. Neurosci. Res. 39 (1994) 377-385
31. Lambert M.P., Velasco P.T., Chang L., Viola K.L., Fernandez S.J., Lacor P.N., Khuon D., Gong Y., Bigio E., Shaw P., De Felice F.G., Krafft G., and Klein W.L. Monoclonal antibodies that target pathological assemblies of Abeta. J. Neurochem. 100 (2007) 23-35
32. Lambert M.P., Viola K.L., Chromy B.A., Chang L., Morgan T.E., Yu J., Venton D.L., Krafft G.A., Finch C.E., and Klein W.L. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79 (2001) 595-605
33. Lee A.W., and States D.J. Both src-dependent and -independent mechanisms mediate phosphatidylinositol 3-kinase regulation of colony-stimulating factor 1-activated mitogen-activated protein kinases in myeloid progenitors. Mol. Cell. Biol. 20 (2000) 6779-6798
34. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
35. Levinthal D.J., and DeFranco D.B. Transient phosphatidylinositol 3-kinase inhibition protects immature primary cortical neurons from oxidative toxicity via suppression of extracellular signal-regulated kinase activation. J. Biol. Chem. 279 (2004) 11206-11213
36. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., and McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293 (2001) 1487-1491
37. Liu S.J., Zhang A.H., Li H.L., Wang Q., Deng H.M., Netzer W.J., Xu H., and Wang J.Z. Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J. Neurochem. 87 (2003) 1333-1344
38. Liu Y., Peterson D.A., and Schubert D. Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 13266-13271
39. Ma Q.L., Lim G.P., Harris-White M.E., Yang F., Ambegaokar S.S., Ubeda O.J., Glabe C.G., Teter B., Frautschy S.A., and Cole G.M. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J. Neurosci. Res. 83 (2006) 374-384
40. Maccioni R.B., Lavados M., Guillon M., Mujica C., Bosch R., Farias G., and Fuentes P. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. Neurobiol. Aging 27 (2006) 237-244
41. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., and Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999) 860-866
42. Michaelis M.L., Dobrowsky R.T., and Li G. Tau neurofibrillary pathology and microtubule stability. J. Mol. Neurosci. 19 (2002) 289-293
43. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
44. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., and Buxbaum J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283 (2000) 1571-1577
45. Oddo S., Caccamo A., Smith I.F., Green K.N., and LaFerla F.M. A dynamic relationship between intracellular and extracellular pools of Abeta. Am. J. Pathol. 168 (2006) 184-194
46. Oddo S., Caccamo A., Tran L., Lambert M.P., Glabe C.G., Klein W.L., and Laferla F.M. Temporal profile of Abeta oligomerization in an in vivo model of Alzheimer's disease: a link between Abeta and tau pathology. J. Biol. Chem. 281 (2005) 1599-1604
47. Rapoport M., Dawson H.N., Binder L.I., Vitek M.P., and Ferreira A. Tau is essential to beta -amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 6364-6369
48. Reiske H.R., Kao S.C., Cary L.A., Guan J.L., Lai J.F., and Chen H.C. Requirement of phosphatidylinositol 3-kinase in focal adhesion kinase-promoted cell migration. J. Biol. Chem. 274 (1999) 12361-12366
49. Rodgers, A.B., November 2005. Progress report on Alzheimer's disease 2004-2005. U.S. Department of Health and Human Services/National Institutes on Aging/National Institutes of Health.
50. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
51. Sonoda Y., Watanabe S., Matsumoto Y., Aizu-Yokota E., and Kasahara T. FAK is the upstream signal protein of the phosphatidylinositol 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line. J. Biol. Chem. 274 (1999) 10566-10570
52. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal longterm potentiation in vivo. Nature 416 (2002) 535-539
53. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
54. Wasilewska-Sampaio A.P., Silveira M.S., Holub O., Goecking R., Gomes F.C.A., Moura Neto V., Linden R., Ferreira S.T., and De Felice F.G. Neuritogenesis and neuronal differentiation promoted by 2,4-dinitrophenol, a novel anti-amyloidogenic compound. FASEB J. 19 (2005) 1627-1636
55. Williamson R., Scales T., Clark B.R., Gibb G., Reynolds C.H., Kellie S., Bird I.N., Varndell I.M., Sheppard P.W., Everall I., and Anderton B.H. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. J. Neurosci. 22 (2002) 10-20
56. Zhang C., Lambert M.P., Bunch C., Barber K., Wade W.S., Krafft G.A., and Klein W.L. Focal adhesion kinase expressed by nerve cell lines shows increased tyrosine phosphorylation in response to Alzheimer's A beta peptide. J. Biol. Chem. 269 (1994) 25247-25250
57. Zhang C., Qiu H.E., Krafft G.A., and Klein W.L. A beta peptide enhances focal adhesion kinase/Fyn association in a rat CNS nerve cell line. Neurosci. Lett. 211 (1996) 187-190